Physician profile
Ronald Arrick
NPI 1104816859
$6,339.57
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $950 · 2021: $1,270 · 2022: $1,250 · 2023: $1,064 · 2024: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $938.96 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $931.73 | 2019-2024 | |
| Abbvie INC. | $615.53 | 2020-2024 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $550.12 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $514.48 | 2019-2024 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $497.17 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.01 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $265.72 | 2019-2022 | |
| Amarin Pharma, INC. | $262.41 | 2019-2020 | |
| Astellas Pharma US INC | $222.85 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.16 | 2019-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $157.11 | 2019-2022 | |
| Amgen INC. | $151.18 | 2019-2023 | Repatha, Otezla |
| Abbott Laboratories | $132.03 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $88.29 | 2021-2024 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $70.57 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.45 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $61.97 | 2021-2023 | Camzyos |
| Phathom Pharmaceuticals, INC. | $35.32 | 2024 | Voquezna |
| Exact Sciences Corporation | $29.82 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $28.68 | 2024 | Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $27.74 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $23.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.00 | 2024 | Austedo Xr |
| Alnylam Pharmaceuticals INC. | $17.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.93 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.92 | 2021 | |
| Evoke Pharma, INC. | $13.80 | 2023 | Gimoti |
| Xeris Pharmaceuticals, INC. | $12.60 | 2022 | |
| Currax Pharmaceuticals LLC | $11.93 | 2021 | |
| Eisai INC. | $11.70 | 2020 | |
| Daiichi Sankyo INC. | $11.70 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Arrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.